@true.lio's tirzepatide weight loss claims, fact-checked
Quick answer
The video implicitly credits tirzepatide with significant waist circumference reduction, which aligns with SURMOUNT-1 trial findings showing average 14.4 cm waist reduction at the 15 mg dose over 72 weeks. The casual mention of facial volume loss reflects a documented consequence of rapid fat mass reduction seen across GLP-1 and dual agonist therapies. No dosing, duration, or clinical supervision details are provided, making individual outcomes impossible to assess from the video alone.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @true.lio actually say?
Honestly, not much, literally. The transcript is almost entirely a playful audio bit, something like "excuse me miss where's your waist" repeated over what is presumably a before-and-after visual transformation. The creator isn't making clinical claims here. They're celebrating a visible waist reduction, tagging a Miami med spa, and using the hashtag #tirzepatideweightloss. The implicit claim is that tirzepatide drove this body composition change.
That's actually a meaningful claim even if it's delivered through a jokey audio overlay. When you slap a GLP-1 drug hashtag on a body transformation video, you're telling your 14,000+ viewers: this medication did this to my body. That deserves scrutiny.
Does the science back this up?
Yes, tirzepatide does produce significant waist circumference reduction, and the data on this is pretty compelling. This isn't just weight loss. It's preferential fat mass reduction with relative lean mass preservation.
In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on the highest dose of tirzepatide (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks. Waist circumference dropped by an average of 14.4 cm in that group. That's a clinically meaningful reduction, not a rounding error. A separate body composition substudy found that roughly two-thirds of weight lost was fat mass, with visceral fat taking a disproportionate hit. So yes, a visibly changed waistline after tirzepatide treatment is biologically plausible and well-supported.
- Jastreboff et al., 2022, NEJM: 20.9% body weight reduction at 15 mg dose
- Waist circumference reduction averaged 14.4 cm in highest dose group
- Fat mass comprised approximately 66-68% of total weight lost
What did they get wrong (or right)?
There's nothing factually wrong here because there are no factual statements. The video is vibes and audio, not claims. Credit where it's due: not making medical claims is sometimes the right move on social media. But the hashtag framing does the work that words don't, and that's worth naming.
What the video can't tell you is anything about dose, duration, diet, exercise, starting weight, or whether surgical or aesthetic procedures also played a role. The Miami med spa tag is notable. Med spa environments vary widely in how they supervise GLP-1 prescribing, and "waist" transformations in that context sometimes involve more than medication alone. The video doesn't claim otherwise, but it doesn't clarify either. That ambiguity is misleading by omission, even if unintentionally.
The face comment, "your face is missing," is a casual nod to GLP-1-associated facial volume loss, sometimes called "Ozempic face" in the press. That phenomenon is real and documented, though it's a function of total fat loss, not a drug-specific effect (Hwang et al., 2023, JAMA Dermatology).
What should you actually know?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which separates it mechanistically from semaglutide. The dual agonism appears to drive larger fat loss than GLP-1 agonism alone, based on head-to-head data from the SURMOUNT-5 trial (Garvey et al., 2024, NEJM). Results like what this video appears to show, dramatic waist reduction, are within the range of what clinical trials report. But trials also show significant individual variability. Not everyone gets a 20% weight loss. Some people get 5%.
The facial volume loss shown in this video is common at high rates of weight loss regardless of mechanism. It's not dangerous, but patients should know it can happen. It's reversible with weight stabilization or dermal filler if desired.
If you're considering tirzepatide, it requires a prescription, medical supervision, and regular follow-up. Compounded tirzepatide is not equivalent to FDA-approved Zepbound or Mounjaro, and availability of compounded versions has shifted as the FDA shortage designation changed in 2025. A regulated telehealth provider with licensed prescribers is a safer starting point than a med spa with variable oversight.
Bottom line
This video shows a real outcome that real clinical data supports. It just doesn't tell you anything useful about how to get there, what the risks are, or what else might be going on. As GLP-1 content goes, it's neither harmful nor particularly informative. The science behind the transformation is solid. The video just isn't doing science.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @true.lio's tirzepatide weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The video implicitly credits tirzepatide with significant waist circumference reduction, which aligns with SURMOUNT-1 trial findings showing average 14.
FormBlends verdict
The video implicitly credits tirzepatide with significant waist circumference reduction, which aligns with SURMOUNT-1 trial findings showing average 14.4 cm waist reduction at the 15 mg dose over 72 weeks. The casual mention of facial volume loss reflects a documented consequence of rapid fat mass reduction seen across GLP-1 and dual agonist therapies. No dosing, duration, or clinical supervision details are provided, making individual outcomes impossible to assess from the video alone.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video implicitly credits tirzepatide with significant waist circumference reduction, which aligns with SURMOUNT-1 trial findings showing average 14.4 cm waist reduction at the 15 mg dose over 72 weeks. The casual mention of facial volume loss reflects a documented consequence of rapid fat mass reduction seen across GLP-1 and dual agonist therapies. No dosing, duration, or clinical supervision details are provided, making individual outcomes impossible to assess from the video alone.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15 mg produced an average 20.9% body weight loss and 14.4 cm waist reduction over 72 weeks.
- Approximately 66-68% of weight lost on tirzepatide is fat mass, with visceral fat disproportionately reduced compared to lean mass.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide 15 mg produced an average 20.9% body weight loss and 14.4 cm waist reduction over 72 weeks.
- Approximately 66-68% of weight lost on tirzepatide is fat mass, with visceral fat disproportionately reduced compared to lean mass.
- Individual responses vary widely: some patients lose 5% body weight, others exceed 20%, and no social media video can predict your outcome.
- Facial volume loss during GLP-1 or dual agonist therapy is a consequence of total fat reduction, not a drug-specific side effect, and is generally reversible.
- Compounded tirzepatide is not equivalent to FDA-approved Zepbound or Mounjaro; the FDA's shortage status for tirzepatide changed in 2025, affecting compounded availability.
- Med spa prescribing environments vary significantly in clinical oversight; tirzepatide requires ongoing medical supervision to manage side effects and titration safely.
- SURMOUNT-5 (Garvey et al., 2024, NEJM) found tirzepatide outperformed semaglutide on body weight reduction in a head-to-head trial, supporting the dual agonist mechanism advantage.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
True L.I.O. | Miami · TikTok creator
14.8K views on this video
Bye bye waist👋🏼💞 @Evette Villanueva #weightlossjourny #miamimedspa #healthiswealth #tirzepatideweightloss #weightlossprogress #happyandhealthy #miamiweightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by True L.I.O. | Miami, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.